A rapid access to addiction medicine clinic facilitates treatment of substance use disorder and reduces substance use

David Wiercigroch, Hasan Sheikh, Jennifer Hulme, David Wiercigroch, Hasan Sheikh, Jennifer Hulme

Abstract

Background: Substance use is prevalent in Canada, yet treatment is inaccessible. The Rapid Access to Addiction Medicine (RAAM) clinic opened at the University Health Network (UHN) in January 2018 as part of a larger network of addictions clinics in Toronto, Ontario, to enable timely, low barrier access to medical treatment for substance use disorder (SUD). Patients attend on a walk-in basis without requiring an appointment or referral. We describe the RAAM clinic model, including referral patterns, patient demographics and substance use patterns. Secondary outcomes include retention in treatment and changes in both self-reported and objective substance use.

Methods: The Electronic Medical Record at the clinic was reviewed for the first 26 weeks of the clinic's operation. We identified SUD diagnoses, referral source, medications prescribed, retention in care and self-reported substance use.

Results: The clinic saw 64 unique patients: 66% had alcohol use disorder (AUD), 39% had opiate use disorder (OUD) and 20% had stimulant use disorder. Fifty-five percent of patients were referred from primary care providers, 30% from the emergency department and 11% from withdrawal management services. Forty-two percent remained on-going patients, 23% were discharged to other care and 34% were lost to follow-up. Gabapentin (39%), naltrexone (39%), and acamprosate (15%) were most frequently prescribed for AUD. Patients with AUD reported a significant decrease in alcohol consumption at their most recent visit. Most patients (65%) with OUD were prescribed buprenorphine, and most patients with OUD (65%) had a negative urine screen at their most recent visit.

Conclusion: The RAAM model provides low-barrier, accessible outpatient care for patients with substance use disorder and facilitates the prescription of evidence-based pharmacotherapy for AUD and OUD. Patients referred by their primary care physician and the emergency department demonstrated a reduction in median alcohol consumption and high rates of opioid abstinence.

Keywords: Addiction; Buprenorphine; Low-barrier; Opioid; Outpatient; RAAM; alcohol; substance use.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Frequency of medications prescribed for alcohol use disorder for on-going patients and patients discharged to other care settings
Fig. 2
Fig. 2
a, b, c Self-reported measures of alcohol consumption for all patients at their initial and most recent visit. 2A: Median and inner quartile range of number of days abstinent per week for all patients at initial visit and at the most recent visit; 2B: Median and inner quartile range of total weekly alcohol consumption for all patients at their initial visit vs. most recent visit; 2C Median and inner quartile range of daily maximum alcohol consumption for all patients at their initial visit and most recent visit
Fig. 3
Fig. 3
a, b, c Self-reported measures of alcohol consumption for all patients at their initial and most recent visit, by referral source. 3A: Median and inner quartile range of number of days abstinent per week for all patients at the initial visit and the most recent visit, by referral source; 3B: Median and inner quartile range of total weekly alcohol for all patients at the initial visit and the most recent visit, by referral source; 3C: Median and inner quartile range of daily maximum alcohol consumption for all patients at initial visit and the most recent visit, by referral source

References

    1. Pearson C, Janz T, Ali J. Mental and substance use disorders in Canada [Internet]. Ottawa. 2015.
    1. Hasin DS, O’Brien CP, Auriacombe M, Borges G, Bucholz K, Budney A, et al. DSM-5 criteria for substance use disorders: Recommendations and rationale. Am J Psychiatry. 2013;170:834–851. doi: 10.1176/appi.ajp.2013.12060782.
    1. Busse JW, Craigie S, Juurlink DN, Buckley DN, Wang L, Couban RJ, et al. Guideline for opioid therapy and chronic noncancer pain. CMAJ. 2017;189(18):E659–E666. doi: 10.1503/cmaj.170363.
    1. Special Advisory Committee on the Epidemic of Opioid Overdoses. National report: Apparent opioid-related deaths in Canada (January 2016 to September 2018) [Internet]. Public Health Agency of Canada. 2018 [cited 2018 Sep 19]. Available from:
    1. Canadian Institute for Health Information, Canadian Centre on Substance Abuse. Hospitalizations and Emergency Department Visits Due to Opioid Poisoning in Canada Hospitalizations and Emergency Department Visits Due to Opioid Poisoning in Canada [Internet]. Ottawa; 2016. Available from:
    1. Gerstein DR, Lewin LS. Treating drug problems. N Engl J Med. 1990;323(12):844–848. doi: 10.1056/NEJM199009203231230.
    1. McCollister KE, French MT. The relative contribution of outcome domains in the total economic benefit of addiction interventions: a review of first findings. Addiction. 2003;98(12):1647–1659. doi: 10.1111/j.1360-0443.2003.00541.x.
    1. Kohn R, Saxena S, Levav I, Saraceno B. The treatment gap in mental health care. Bull World Heal Organ. 2004;82(11):858–866.
    1. Vipler S, Hayashi K, Milloy M-J, Wood E, Nosova E, Kerr T, et al. Use of withdrawal management services among people who use illicit drugs in Vancouver, Canada. Subst Abuse Treat Prev Pol. 2018;13(1):27. doi: 10.1186/s13011-018-0164-3.
    1. Keen J, Oliver P, Rowse G, Mathers N. Residential rehabilitation for drug users: a review of 13 months’ intake to a therapeutic community. Fam Pr. 2001;18(5):545–548. doi: 10.1093/fampra/18.5.545.
    1. Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry. 2015;23(2):63–75. doi: 10.1097/HRP.0000000000000075.
    1. Festinger DS, Lamb RJ, Kountz MR, Kirby KC, Marlowe D. Pretreatment dropout as a function of treatment delay and client variables. Addict Behav. 1995;20(1):111–115. doi: 10.1016/0306-4603(94)00052-Z.
    1. Ross LE, Vigod S, Wishart J, Waese M, Spence JD, Oliver J, et al. Barriers and facilitators to primary care for people with mental health and/or substance use issues: a qualitative study. BMC Fam Pract. 2015;16(1):135. doi: 10.1186/s12875-015-0353-3.
    1. Levinson Miller C, Druss BG, Dombrowski EA, Rosenheck RA. Barriers to Primary Medical Care Among Patients at a Community Mental Health Center. Psychiatr Serv. 2003;54(8):1158–1160. doi: 10.1176/appi.ps.54.8.1158.
    1. Mandelberg JH, Kuhn RE, Kohn MA. Epidemiologic analysis of an urban, public emergency department’s frequent users. Acad Emerg Med. 2000;7(6):637–646. doi: 10.1111/j.1553-2712.2000.tb02037.x.
    1. McLellan AT, Starrels JL, Tai B, Gordon AJ, Brown R, Ghitza U, et al. Can Substance Use Disorders be Managed Using the Chronic Care Model? Review and Recommendations from a NIDA Consensus Group. Public Health Rev. 2014;35(2) [cited 2019 Mar 14] Available from: .
    1. Gee PM, Greenwood DA, Paterniti DA, Ward D, LMS M. The eHealth enhanced chronic care model: A theory derivation approach. J Med Internet Res. 2015;17:e86. doi: 10.2196/jmir.4067.
    1. Netherland J, Botsko M, Egan JE, Fiellin DA, Saxon AJ, Cunningham CO, et al. Factors affecting willingness to provide buprenorphine treatment. J Subst Abuse Treat. 2008;36(3):244–251. doi: 10.1016/j.jsat.2008.06.006.
    1. META:PHI. Mentoring, Education, and Clinical Tools for Addiction: Primary Care-Hospital Integration. A provincial initiative to support health care providers in treating people struggling with substance use disorders [Internet]. Women’s College Hospital. 2018. Available from:
    1. Longabaugh R, Minugh PA, Nirenberg TD, Clifford PR, Becker B, Woolard R. Injury as a motivator to reduce drinking. Acad Emerg Med. 1995;2(9):817–825. doi: 10.1111/j.1553-2712.1995.tb03278.x.
    1. Trowbridge P, Weinstein ZM, Kerensky T, Roy P, Regan D, Samet JH, et al. Addiction consultation services - Linking hospitalized patients to outpatient addiction treatment. J Subst Abuse Treat. 2017;79:1–5. doi: 10.1016/j.jsat.2017.05.007.
    1. Moallem NR, Courtney KE, Bacio GA, Ray LA. Modeling alcohol use disorder severity: An integrative structural equation modeling approach. Front Psychiatry. 2013;4(JUL):75.
    1. Butt P, Beriness D, Gliksman L, Paradis C, Stockwell T. Alcohol and health in Canada: A summary of evidence and guidelines for low risk drinking [Internet]. Ottawa. 2011.
    1. Family Health Teams [Internet]. Ontario Ministry of Health and Long-Term Care. 2016. Available from:
    1. Friedmann PD, Lemon SC, Stein MD, D’Aunno TA. Accessibility of addiction treatment: results from a national survey of outpatient substance abuse treatment organizations. Heal Serv Res. 2003;38(3):887–903. doi: 10.1111/1475-6773.00151.
    1. Kaplan EH, Johri M. Treatment on demand: an operational model. Heal Care Manag Sci. 2000;3(3):171–183. doi: 10.1023/A:1019001726188.
    1. R Core Team. R . A language and environment for statistical computing [Internet] Vienna, Austria: R foundation for Statistical Computing; 2017.
    1. Miller JM. GraphPad PRISM. Vol. 52, Analysis. San Diego, California: GraphPad Software; 2003. pp. 2–3.
    1. Fischer B, Argento E. Prescription opioid related misuse, harms, diversion and interventions in Canada: a review. Pain Physician. 2012;15(3 Suppl):ES191–ES203.
    1. Spithoff S, Turner S, Gomes T, Martins D, Singh S. First-line medications for alcohol use disorders among public drug plan beneficiaries in Ontario. Can Fam Physician. 2017;63(5):e277–e283.
    1. Bruneau J, Ahamad K, Goyer M, Poulin G, Selby P, Fischer B, et al. Management of opioid use disorders: a national clinical practice guideline. CMAJ. 2018;190(9):E247–E257. doi: 10.1503/cmaj.170958.
    1. Socías ME, Ahamad K. An urgent call to increase access to evidence-based opioid agonist therapy for prescription opioid use disorders. CMAJ. 2016;188(17–18):1208–1209. doi: 10.1503/cmaj.160554.
    1. Blow FC, Walton MA, Barry KL, Murray RL, Cunningham RM, Massey LS, et al. Alcohol and drug use among patients presenting to an inner-city emergency department: A latent class analysis. Addict Behav. 2011;36(8):793–800. doi: 10.1016/j.addbeh.2010.12.028.
    1. Trinks A, Festin K, Bendtsen P, Cherpitel CJ, Nilsen P. Acute alcohol consumption and motivation to reduce drinking among injured patients in a Swedish emergency department. J Addict Nurs. 2012;23(3):152–158. doi: 10.1097/JAN.0b013e31826f4bbd.
    1. Hu T, Snider-Adler M, Nijmeh L, Pyle A. Buprenorphine/naloxone induction in a Canadian emergency department with rapid access to community-based addictions providers. CJEM. 2019:1–7 [cited 2019 Jun 4] Available from: .
    1. Wiclkzer T, Maynard C, Atherly A, Frederick MPHM, Koepsell T, Knrpsk A, et al. Completion Rates of Clients Discharged from Drug and Alcohol Treatment Programs in Washington State. Am J Public Health. 1994;84(2):215–221. doi: 10.2105/AJPH.84.2.215.
    1. Liebschutz JM, Crooks D, Herman D, Anderson B, Tsui J, Meshesha LZ, et al. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial. JAMA Intern Med. 2014;174(8):1369–1376. doi: 10.1001/jamainternmed.2014.2556.
    1. Bell J, Trinh L, Butler B, Randall D, Rubin G. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction. 2009;104(7):1193–1200. doi: 10.1111/j.1360-0443.2009.02627.x.
    1. Tuithof M, ten Have M, van den Brink W, Vollebergh W, de Graaf R. Alcohol consumption and symptoms as predictors for relapse of DSM-5 alcohol use disorder. Drug Alcohol Depend. 2014;140:85–91. doi: 10.1016/j.drugalcdep.2014.03.035.
    1. Miller MM. Evaluating Addiction Treatment Outcomes. Addict Disord Their Treat. 2007;6(3):101–106. doi: 10.1097/01.adt.0000210723.64058.d9.
    1. Mccaul ME, Svikis DS, Moore RD. Predictors of outpatient treatment retention: patient versus substance use characteristics [Internet]. Vol. 62. Drug Alcohol Dependence. 2001; [cited 2019 Nov 10]. Available from: .

Source: PubMed

3
S'abonner